466 related articles for article (PubMed ID: 23801739)
1. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
[TBL] [Abstract][Full Text] [Related]
3. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
4. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
5. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
Gonçalves N; Simões AT; Cunha RA; de Almeida LP
Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
[TBL] [Abstract][Full Text] [Related]
6. Lithium chloride therapy fails to improve motor function in a transgenic mouse model of Machado-Joseph disease.
Duarte-Silva S; Neves-Carvalho A; Soares-Cunha C; Teixeira-Castro A; Oliveira P; Silva-Fernandes A; Maciel P
Cerebellum; 2014 Dec; 13(6):713-27. PubMed ID: 25112410
[TBL] [Abstract][Full Text] [Related]
7. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Déglon N; de Almeida LP
PLoS One; 2014; 9(8):e100086. PubMed ID: 25144231
[TBL] [Abstract][Full Text] [Related]
8. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.
Silva-Fernandes A; Duarte-Silva S; Neves-Carvalho A; Amorim M; Soares-Cunha C; Oliveira P; Thirstrup K; Teixeira-Castro A; Maciel P
Neurotherapeutics; 2014 Apr; 11(2):433-49. PubMed ID: 24477711
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease.
Duarte-Neves J; Gonçalves N; Cunha-Santos J; Simões AT; den Dunnen WF; Hirai H; Kügler S; Cavadas C; Pereira de Almeida L
Hum Mol Genet; 2015 Oct; 24(19):5451-63. PubMed ID: 26220979
[TBL] [Abstract][Full Text] [Related]
10. Ibuprofen enhances synaptic function and neural progenitors proliferation markers and improves neuropathology and motor coordination in Machado-Joseph disease models.
Mendonça LS; Nóbrega C; Tavino S; Brinkhaus M; Matos C; Tomé S; Moreira R; Henriques D; Kaspar BK; Pereira de Almeida L
Hum Mol Genet; 2019 Nov; 28(22):3691-3703. PubMed ID: 31127937
[TBL] [Abstract][Full Text] [Related]
11. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
[TBL] [Abstract][Full Text] [Related]
12. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
[TBL] [Abstract][Full Text] [Related]
13. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
14. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
[TBL] [Abstract][Full Text] [Related]
15. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
16. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
17. Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease.
Simões AT; Gonçalves N; Nobre RJ; Duarte CB; Pereira de Almeida L
Hum Mol Genet; 2014 Sep; 23(18):4932-44. PubMed ID: 24817574
[TBL] [Abstract][Full Text] [Related]
18. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
19. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
20. N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation.
Hübener J; Vauti F; Funke C; Wolburg H; Ye Y; Schmidt T; Wolburg-Buchholz K; Schmitt I; Gardyan A; Driessen S; Arnold HH; Nguyen HP; Riess O
Brain; 2011 Jul; 134(Pt 7):1925-42. PubMed ID: 21653538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
